Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.46 |
| ▸ | GSK3B | P49841 | 12/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.45 |
| ▸ | GSK3A | P49840 | 4/20 | 0.45 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | CDK9 | P50750 | 2/20 | 0.45 |
| ▸ | CDK3 | Q00526 | 2/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL764233 | 0.83 | MAPK14 (0.53) | MAPK14GSK3BMAPK10MAPK8GSK3A | |
| SCHEMBL2401052 | 0.77 | GSK3B (0.73) | MAPK14GSK3BMAPK10MAPK8GSK3A | |
| SCHEMBL2401056 | 0.77 | GSK3B (0.73) | MAPK14GSK3BMAPK10MAPK8GSK3A | |
| SCHEMBL26015948 | 0.71 | CDK9 (0.48) | GSK3BGSK3ACDK1CDK2CDK9 | |
| SCHEMBL13060366 | 0.70 | MAPK14 (0.48) | MAPK14MAPK10 | |
| SCHEMBL765896 | 0.70 | AXL (0.55) | MAPK14GSK3BMAPK10MAPK8GSK3A | |
| SCHEMBL30203532 | 0.70 | CDK9 (0.61) | MAPK14GSK3BMAPK10MAPK8GSK3A | |
| SCHEMBL5216885 | 0.67 | CHRM4 (0.53) | — | |
| SCHEMBL751261 | 0.67 | MAPK14 (0.40) | MAPK14GSK3BCDK2 | |
| SCHEMBL18208382 | 0.67 | HPGD (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1439174-B1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS AS p38 MAP KINASE INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-7846933-B2 | such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | KUBO AKIRA | 2009-04-02 | — | — | US | disclosed |
| US-7473695-B2 | 4-imidazolin-2-one compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | OR10J3, NR4A3, NR3C2 | MAPK14 2186/4885GSK3B 3230/4885MAPK10 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.